Comparative Pharmacology
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus ZOLEDRONIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus ZOLEDRONIC.
ETIDRONATE DISODIUM vs ZOLEDRONIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, suppressing crystal dissolution and reducing bone turnover.
Inhibits osteoclast-mediated bone resorption via binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis.
Paget disease: 5-10 mg/kg/day orally, given as a single dose or divided every 12 hours, for up to 6 months; or 300 mg intravenously over at least 2 hours daily for 3 days. Heterotopic ossification: 20 mg/kg/day orally for 2 weeks pre- and 12 weeks post-surgery. Hypercalcemia of malignancy: 7.5 mg/kg intravenously over 4 hours daily for 3-7 days.
5 mg intravenously over at least 15 minutes once yearly for the treatment of osteoporosis, Paget's disease, or hypercalcemia of malignancy; for prevention of skeletal-related events in multiple myeloma or bone metastases: 4 mg intravenously over at least 15 minutes every 3-4 weeks.
None Documented
None Documented
Clinical Note
moderateZoledronic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Zoledronic acid
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid."
Clinical Note
moderateCarprofen + Zoledronic acid
"The risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid."
Clinical Note
moderateTerminal half-life: 1-6 hours after single dose; prolonged to up to 2 weeks in bone due to slow release from hydroxyapatite.
The terminal elimination half-life of zoledronic acid is approximately 146 hours (range 44-196 hours) after a single intravenous dose. This long half-life reflects slow release from bone rather than systemic clearance. Despite the prolonged terminal phase, the clinical effect (suppression of bone resorption) persists for weeks to months. The initial distribution half-life is about 0.23 hours, and the intermediate half-life is about 1.75 hours.
Renal: 30-50% of absorbed dose excreted unchanged in urine; biliary/fecal: minimal, with approximately 5% excreted in feces.
Zoledronic acid is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. Approximately 39 ± 16% of the administered dose is recovered in urine within 24 hours, with the remainder (up to 60%) retained in bone and slowly released over time. Fecal excretion is negligible (<1%). Renal clearance is dose-dependent and correlates with creatinine clearance. Dose adjustment is required for creatinine clearance <35 mL/min.
Category C
Category C
Bisphosphonate
Bisphosphonate
Thalidomide + Zoledronic acid
"The risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid."